Antibody–drug conjugates come of age in oncology
C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …
Emerging new therapeutic antibody derivatives for cancer treatment
S **, Y Sun, X Liang, X Gu, J Ning, Y Xu… - Signal transduction and …, 2022 - nature.com
Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …
enhance natural immune system functions to suppress cancer cell activity and eliminate …
[HTML][HTML] Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
H Tilly, F Morschhauser, LH Sehn… - … England Journal of …, 2022 - Mass Medical Soc
Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …
CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y **ao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Antibody–drug conjugates for cancer
CH Chau, PS Steeg, WD Figg - The Lancet, 2019 - thelancet.com
Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …
Antibody–drug conjugates for cancer therapy
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …
[HTML][HTML] The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell …
Background For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline
treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or …
treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or …
Synthetic biomarkers: a twenty-first century path to early cancer detection
Detection of cancer at an early stage when it is still localized improves patient response to
medical interventions for most cancer types. The success of screening tools such as cervical …
medical interventions for most cancer types. The success of screening tools such as cervical …
Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)
PURPOSE Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in
relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent …
relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent …
Antibody–drug conjugates: A review of approved drugs and their clinical level of evidence
Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …